Previous 10 | Next 10 |
Over the past couple of years, Bellicum Pharmaceuticals has made several changes that have streamlined their pipeline and their OpEx. Consequently, I have had to adjust my thesis and expectations. Bellicum was only a few quarters away from being a commercial company and collecting rev...
Bellicum Pharmaceuticals, Inc. (BLCM) Q4 2020 Earnings Conference Call March 30, 2021, 17:00 ET Company Participants Robert Uhl - Westwicke Partners Richard Fair - President, CEO & Director Conference Call Participants Wangzhi Li - Ladenburg Thalmann & Co. Presentation Operator Greeti...
Bellicum Pharmaceuticals (BLCM): Q4 GAAP EPS of $0.98 beats by $2.04.Revenue of $0.5M (-90.3% Y/Y).Cash and cash equivalents and restricted cash totaling $37.0 million as of December 31, 2020, compared to $93.8 million as of December 31, 2019.“We are excited to have resumed our trial o...
Enrolled first patient in Phase 1/2 clinical trial for BPX-603 in solid tumors that express HER2 Clinical hold lifted on Phase 1/2 dose-escalation trial evaluating BPX-601 and rimiducid in patients with previously treated metastatic prostate or pancreatic cancer Conferen...
HOUSTON, March 23, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it will report financial results for the fourth quarter and full year 2020 after the close of U.S. marke...
HOUSTON, March 04, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the publication of a case report using the company’s CaspaCIDe (inducible caspase-9, or iC9) safe...
Ponce Therapeutics Inc. Commences First R & D Program in Anti-Aging Products for Skin Ponce Therapeutics Inc. Commences First R & D Program in Anti-Aging Products for Skin Rapha Capital Management Leads Convertible Note Financing PR Newswire MIAMI , ...
Gainers: Catabasis Pharmaceuticals (CATB) +162%, Novavax (NVAX) +66%, Bellicum Pharmaceuticals (BLCM) +40%, 9 Meters Biopharma (NMTR) +32%, Regional Health Properties (RHE) +9%.Losers: iRhythm Technologies (IRTC) -36%, Lianluo Smart (LLIT) -19...
Will These Biotech Penny Stocks Continue to Make Moves Next Month? With February right around the corner, we see heightened momentum in the stock market. After the Gamestop Corp. ( NYSE: GME ) debacle on Wednesday, January 27th, traders are figuring out how to find the best pe...
Siebert Financial (SIEB) +453%.LM Funding America (LMFA) +101%.GameStop (GME) +75%.Koss Corporation (KOSS) +63%.Novavax (NVAX) +60% as its COVID-19 vaccine shows 89% efficacy in UK, 60% in South Africa.Catabasis Pharmaceuticals (CATB) +51% after announcing acquisition of Quellis Bio...
News, Short Squeeze, Breakout and More Instantly...
Bellicum Pharmaceuticals Inc. Company Name:
BLCM Stock Symbol:
NASDAQ Market:
Bellicum Pharmaceuticals Inc. Website:
Carisma Therapeutics Inc. (CARM) is expected to report $-0.56 for Q4 2023 First Acceptance Corp. (FACO) is expected to report for quarter end 2023-12-31 Bell Copper Corp (BCUFF) is expected to report for quarter end 2023-12-31 BioHarvest Sciences Inc (CNVCF) is expected to report for ...
First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...
Kajima Corporation ADR (KAJMY) is expected to report for quarter end 2023-12-31 FaZe Holdings Inc. (FAZE) is expected to report for Q4 2023 BrewBilt MFG Inc (BBRW) is expected to report for Q4 2023 Correlate Energy Corp. (CIPI) is expected to report for Q4 2023 Hyzon Motors Inc. (...